Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIFT I: ABT-450/r/ABT-267 in Japanese adults with HCV genotype 1b
jRCT2080222350Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ombitasvir + paritaprevir + ritonavir in chronic hepatitis C (CHC), sponsored by AbbVie Inc.
02
Drugs
ombitasvir + paritaprevir + ritonavir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080222350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222350.